Johnson & Johnson Faces $1 Billion Penalty

Johnson Johnson

Johnson & Johnson faces a staggering $1 billion penalty after a court ruled its surgical robot technology fell short of promises.

At a Glance

  • Johnson & Johnson must pay $1 billion in damages for breaches of contract and fraud related to surgical robotics.
  • The ruling affects the iPlatform and other planned robotics developments.
  • Johnson & Johnson disagrees with the decision and is contemplating an appeal.
  • This case does not impact the company’s current robotics program.

Johnson & Johnson Penalized Over Surgical Robot Technology

Delaware judge orders Johnson & Johnson (J&J) to pay over $1 billion in damages for breaching an acquisition agreement with Auris Health Inc. The court found that J&J failed to deliver on the contractual obligations tied to surgical robots, particularly the iPlatform. Vice Chancellor Lori W. Will ruled that J&J neglected its promises for regulatory approval nearly immediately after acquiring Auris for $3.4 billion in 2019.

The crux of the case involves J&J’s iPlatform and Monarch surgical robot technologies, developed for soft tissue ablation. Auris’s former shareholders claimed that J&J did not meet key milestones, which would have enabled additional earnout payments to the shareholders. According to the court, J&J diverted resources from the iPlatform in favor of its internally competitive project, Verb.

Vice Chancellor Will’s 145-page opinion indicated that commercial promises were not kept, leading to failures in achieving initial iPlatform milestones. As a result, subsequent targets were unattainable, causing significant financial repercussions. The judgment marks a victory for Ross Aronstam & Moritz and Selendy Gay PLLC, the law firms representing the Auris shareholders in this high-profile case.

Company Disputes Court Decision

Johnson & Johnson disagrees with the court’s decision and is reviewing potential for appeal. The company criticized the ruling via a spokesperson on Wednesday, noting, “Fundamentally, the court viewed our commercially reasonable contract as imposing a commercially unreasonable obligation.” This statement underscores their stance on an otherwise controversial judgment that significantly impacts the medical technology landscape.

“We respectfully disagree with the court’s decision regarding our development of the iPlatform and communications with Auris regarding soft tissue ablation,” a Johnson & Johnson spokesperson said.

Importantly, the ruling does not affect Johnson & Johnson’s current robotics initiatives or the forthcoming Ottava surgical robotics system. The company emphasized in their statement that the decision is isolated to the Auris merger and only pertains to past actions, not the future trajectory of J&J’s robotics endeavors.

Implications for Medical Technology Companies

This ruling serves as a grim reminder for medical technology companies about the critical importance of fulfilling marketing claims and contractual promises. Failures to meet such promises can result in severe financial and reputational damages, as seen in this landmark case. The court underscored that J&J’s actions led to missed milestones and ultimately delayed the transformative potential of Auris’ robots.

“J&J’s promise to Auris was broken almost immediately,” Vice Chancellor Lori W. Will said in a 145-page opinion. Although the damages will compensate the Auris ex-investors, “what remains irretrievably lost is the transformative potential of Auris’ robots.”

As J&J considers its next steps, the broader medical technology community waits to see how this ruling may influence future corporate behavior and regulatory strategies. The lawsuit, titled Fortis & Fortis Advisors LLC v. Johnson & Johnson, stands as a cautionary tale for pushing technological boundaries without delivering on commitments.

​

RELATED ARTICLESMORE FROM AUTHOR